Actively Recruiting
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
Led by Stichting Hemato-Oncologie voor Volwassenen Nederland · Updated on 2024-08-19
599
Participants Needed
38
Research Sites
707 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
In the Netherlands, the standard treatment for multiple myeloma is a combination of different medicines named daratumumab-lenalidomide-dexamethasone, abbreviated as Dara-Rd. In many patients this treatment results in suppressing the disease for a long time. The treatment is continued until it is not effective anymore and the disease progresses. But until now it is unknown whether continuous therapy also leads to prolonging life. In addition, there are concerns about side effects, leading to a reduced quality of life, the development of severe toxicity that remains, which hampers subsequent therapy, and high costs due to prolonged treatment. There are indications that temporarily stopping treatment is safe, leading to fewer side effects and allows recovering from toxicity or damage due to treatment. This may improve the quality of life.
CONDITIONS
Official Title
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with multiple myeloma based on IMWG criteria with measurable disease at diagnosis
- Aged 18 years or older
- Treated with 12 (or 13) cycles of daratumumab-lenalidomide-dexamethasone and planning to continue this treatment
- Achieved partial response or better after 12 cycles without biochemical progression
- Absolute neutrophil count (ANC) of 1.0 x 10^9/L or higher and platelets of 75 x 10^9/L or higher
- Able to provide informed consent
- Provided written informed consent
You will not qualify if you...
- Non-secretory multiple myeloma at diagnosis before starting Dara-Rd treatment
- Only plasmacytoma as a measurable parameter at diagnosis before starting Dara-Rd
- Only urine M-protein as a measurable parameter at diagnosis before starting Dara-Rd
- Discontinued daratumumab or lenalidomide treatment for any reason (dexamethasone discontinuation allowed)
- Continuing Dara-Rd treatment not feasible for medical reasons
- Psychological, familial, sociological, or geographical conditions that may affect compliance with study protocol and follow-up
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 38 locations
1
NL-Den Bosch-JBZ
's-Hertogenbosch, Netherlands
Actively Recruiting
2
NL-Almere-FLEVOZIEKENHUIS
Almere Stad, Netherlands
Actively Recruiting
3
NL-Amersfoort-MEANDERMC
Amersfoort, Netherlands
Actively Recruiting
4
NL-Amsterdam- UMC
Amsterdam, Netherlands
Actively Recruiting
5
NL-Amsterdam-AmsterdamUMC
Amsterdam, Netherlands
Actively Recruiting
6
NL-Apeldoorn-GELREAPELDOORN
Apeldoorn, Netherlands
Actively Recruiting
7
NL-Arnhem-RIJNSTATE
Arnhem, Netherlands
Actively Recruiting
8
NL-Assen-WZA
Assen, Netherlands
Actively Recruiting
9
NL-Beverwijk-RKZ
Beverwijk, Netherlands
Actively Recruiting
10
NL-Delft-RDGG
Delft, Netherlands
Actively Recruiting
11
NL-Deventer-DZ
Deventer, Netherlands
Actively Recruiting
12
NL-Dordrecht-ASZ
Dordrecht, Netherlands
Actively Recruiting
13
Nij Smellinghe Ziekenhuis
Drachten, Netherlands
Actively Recruiting
14
NL-Ede-ZGV
Ede, Netherlands
Actively Recruiting
15
NL-Emmen-SCHEPER
Emmen, Netherlands
Actively Recruiting
16
NL-Enschede-MST
Enschede, Netherlands
Actively Recruiting
17
NL-Goes-ADRZ
Goes, Netherlands
Actively Recruiting
18
NL-Gorinchem-BEATRIX
Gorinchem, Netherlands
Actively Recruiting
19
NL-Groningen-MARTINI
Groningen, Netherlands
Actively Recruiting
20
NL-Hardenberg-SAXENBURGH
Hardenberg, Netherlands
Actively Recruiting
21
NL-Harderwijk-STJANSDALHARDERWIJK
Harderwijk, Netherlands
Actively Recruiting
22
NL-Helmond-ELKERLIEK
Helmond, Netherlands
Actively Recruiting
23
NL-Hilversum-TERGOOI
Hilversum, Netherlands
Actively Recruiting
24
NL-Hoofddorp-SPAARNEGASTHUIS
Hoofddorp, Netherlands
Actively Recruiting
25
NL-Hoorn-DIJKLANDERHOORN
Hoorn, Netherlands
Actively Recruiting
26
Alrijne Ziekenhuis Leiderdorp
Leiderdorp, Netherlands
Actively Recruiting
27
HMC Antoniushove
Leidschendam, Netherlands
Actively Recruiting
28
NL-Roosendaal-BRAVIS
Roosendaal, Netherlands
Actively Recruiting
29
NL-Rotterdam-IKAZIA
Rotterdam, Netherlands
Actively Recruiting
30
NL-Schiedam-FRANCISCUSVLIETLAND
Schiedam, Netherlands
Actively Recruiting
31
NL-Sittard-Geleen-ZUYDERLAND
Sittard, Netherlands
Actively Recruiting
32
NL-Sneek-ANTONIUSSNEEK
Sneek, Netherlands
Actively Recruiting
33
NL-Terneuzen-ZORGSAAM
Terneuzen, Netherlands
Actively Recruiting
34
NL-Tilburg-ETZ
Tilburg, Netherlands
Actively Recruiting
35
NL-Uden-BERNHOVEN
Uden, Netherlands
Actively Recruiting
36
NL-Venlo-VIECURI
Venlo, Netherlands
Actively Recruiting
37
NL-Zaandam-ZAANSMC
Zaandam, Netherlands
Actively Recruiting
38
NL-Zwolle-ISALA
Zwolle, Netherlands
Actively Recruiting
Research Team
S
Sonja Zweegman, Prof Dr MD
CONTACT
M
Maarten Seefat, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here